QFG Asks WHO to Consider the Lives of a Billion Smokers in Panama Talks
29 Jan 2024
MANILA, Philippines, Jan. 29, 2024 /PRNewswire/ -- Consumer advocacy group Quit for Good asked the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) to consider the lives of more than a billion smokers when it convenes the 10th Conference of the Parties in Panama next week.
Dr. Lorenzo Mata Jr., president of Quit for Good, said the WHO should implement FCTC Article 1 (d) on harm reduction strategies to help smokers. The treaty defines tobacco control as "a range of supply, demand and harm reduction strategies."
Continue Reading
Preview
Source: PRNewswire
"Consider the lives of more than a billion smokers" - Dr. Lorenzo Mata of QFG, Nancy Loucas of CAPRHA and Prof. Jay Jazul of HARAP
"Offering safer nicotine products to millions of adult smokers who want to reduce their exposure to toxic substances from smoke is common sense. This is what tobacco harm reduction (THR) is all about, which the WHO FCTC refuses to implement despite being part of the global treaty," Dr. Mata said.
Representatives from countries that are signatories to the WHO FCTC will meet in Panama for the 10th Conference of the Parties this year, after the meeting was cancelled in November 2023, to tackle major topics such as how to treat "novel and emerging tobacco and nicotine products".
The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) said blocking the use of products that can help save smokers' lives is against the mission of the WHO FCTC—a global treaty endorsed by most countries.
"People who smoke should have the right to access less harmful alternatives to smoking, and the WHO FCTC should focus on helping them. We need a pragmatic campaign to reduce the harm caused by smoking, rather than a dogmatic, deceptive, ineffective campaign to compel abstinence," CAPHRA executive coordinator Nancy Loucas said.
Loucas said the annual reviews of the Office for Health Improvement and Disparities, formerly Public Health England, have consistently shown that vaping carries a fraction of the risks of smoking. "Despite the overwhelming scientific evidence supporting vaping products as less harmful alternatives to smoking, the WHO has consistently disregarded the positive role that vaping can play in tobacco control," she said.
"It is time for the WHO FCTC and its member states to listen to the voice of the people that they are supposed to fight for and not against—the over 1 billion smokers whose lives are in danger if they continue to smoke," she said.
Prof. Jay Jazul, Lead Convener of the Harm Reduction Alliance of the Philippines (HARAP), said: "E-cigarettes do not threaten public health but provide smokers with an exit from smoking, which is the real problem. The WHO's failure to substantiate its claims against e-cigarettes and labeling these innovative products an emerging threat to public health is worrisome."
"The nicotine was not the problem, it was the delivery system that was the problem. We've known that for 50 years," said Professor David Sweanor of the University of Ottawa at a recent conference in Korea.
"The best example of how products that don't burn tobacco can benefit public health comes from Sweden, which has the lowest smoking prevalence among men in the European Union and consequently the lowest tobacco-related mortality," said Dr. Lars M. Ramström, the principal investigator at the Institute for Tobacco Studies. Dr. Ramström served as a WHO expert and as secretary general of the 4th World Conference on Smoking and Health.
"The meeting of the world's health leaders in Panama, the COP10, represents a unique opportunity to take a fresh look at the most recent evidence with an open mind. After all, if Sweden had followed WHO's advice from twenty years ago and banned snus, tobacco-related deaths in Sweden would have been much higher and the only unintended beneficiary profiting from such advice would be the cigarette industry," added Ramström.
Contact:
Jeimie Franco
+639175593170
[email protected]
SOURCE Quit For Good
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.